The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Role of Blood-Brain Barrier in Alzheimer’s Disease
Abstract
The blood-brain barrier (BBB) is involved in the pathogenesis of Alzheimer's disease (AD). BBB is a highly selective semipermeable structural and chemical barrier which ensures a stable internal environment of the brain and prevents foreign objects invading the brain tissue. BBB dysfunction induces the failure of Aβ transport from brain to the peripheral circulation across the BBB. Especially, decreased levels of LRP-1 (low density lipoprotein receptor-related protein 1) and increased levels of RAGE (receptor for advanced glycation endproducts) at the BBB can cause the failure of Aβ transport. The pathogenesis of AD is related to the BBB structural components, including pericytes, astrocytes, vascular endothelial cells, and tight junctions. BBB dysfunction will trigger neuroinflammation and oxidative stress, then enhance the activity of β-secretase and γ-secretase, and finally promote Aβ generation. A progressive accumulation of Aβ in brain and BBB dysfunction may become a feedback loop that gives rise to cognitive impairment and the onset of dementia. The correlation between BBB dysfunction and tau pathology has been well-reported. Therefore, regulating BBB function may be a new therapeutic target for treating AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661 · cited 2×
“TheBBBhasthemostimpor-tantroleinmaintainingbrainfunctionamongthe threebrainbarriers[14,15].”
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670 · cited 1×
“Pericytes, an important component of neurovascular unit and BBB, act like the gatekeepers of the BBB, and exquisitely regulate the movement of brain cellsandthetransportationofnutrientsandmoleculesbetweenthebloodandthebraininterstitialfluidthatsurroundsthebraincells [87–89].”
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier
Huber, J. D., Egleton, R. D., & Davis, T. P. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02004-x · Cited by 786 · cited 1×
“…or progression of numerous brain diseases, such as hemorrhagic and ischemic stroke, intracranial infectious diseases, intracranial autoimmune diseases, epilepsy, lupus cerebritis, and brain tumors [105, 106], as well as neurodegenerative diseases like Parkinson’s disease and AD [45, 107].”
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · cited 7×
“Second,A (cid:2) pathology suffering from BBB dysfunction can indirectly facilitate the onset of tau pathology, representing a mechanistic link between A (cid:2) /tau deposition after BBB dysfunction [1, 126].”
InfluentialAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 2×
“528 Yet, the role of BBB in the pathogenesis of AD is 529 still a challenge [12, 132].”
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670
Halliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649
Research works printed but not linked: 1
- Volpina, 2015, [Fragment of receptor for advanced glycation end products improves memory state in a model of Alzheimer’s disease, Bioorg Khim, 41, 709
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“The presence of BBB avoids the brain from damage by keeping a stable environment.(28,29) But it also limits the drugs that enter into the CNS for treating brain diseases such as neurodegenerative diseases and brain cancer.”
BackgroundHan, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
“…the molecular mechanisms responsible for BBB function and much attention has been paid to BBB deterioration in neurological diseases including AD, as extensively reviewed (Cai et al., 2018; Costea et al., 2019; Profaci et al., 2020; Sweeney et al., 2018, 2019b; Yamazaki and Kanekiyo, 2017).”
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 297
Magnetic iron oxide nanoparticles for brain imaging and drug delivery
Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114822 · Cited by 245
Metadata
- Authors
- Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q.
- Affiliations
- Department of Neurology, Chongqing General Hospital, Chongqing, Chongqing, China
- Corresponding author
- Cai, Zhiyou
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-05-30
- Volume
- 63
- Issue
- 4
- Pages
- 1223-1234
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2804234159
- Cited by
- 370
- References
- 133
- Citations by year
- 2026: 31 · 2025: 59 · 2024: 63 · 2023: 69 · 2022: 49 · 2021: 63 · 2020: 25 · 2019: 10 · 2018: 1
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, Alzheimer's disease
- MeSH terms
- Receptor for Advanced Glycation End Products, Alzheimer Disease, Blood-Brain Barrier, Humans, Amyloid beta-Peptides, Low Density Lipoprotein Receptor-Related Protein-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Blood-Brain Barrier in Alzheimer’s Disease. https://app.cochat.ai/papers/10.3233/jad-180098
- The paper
- Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018). Role of Blood-Brain Barrier in Alzheimer’s Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-180098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.